Image-Guided Thyroid Ablation versus Surgery for T1N0M0 Papillary Thyroid Carcinoma: A Consensus-Aligned Systematic Review and Meta-Analysis.

Balkan Med JAug 26, 2026 (epub)
Clinical ResearchEndocrinologyOncology (Medical)General Surgery

Mustafa Şahin, Atilla Halil Elhan, Giovanni Mauri

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared image-guided thyroid ablation (IGTA) with surgery for T1N0M0 papillary thyroid carcinoma (PTC). The analysis revealed that surgery had lower odds of recurrence (OR = 0.64) but higher overall complications (OR = 2.75) compared to IGTA, suggesting IGTA as a viable, minimally invasive option for selected patients.

Key findings

  • Surgery had significantly higher odds of overall complications compared to IGTA (OR = 2.75).
  • Surgery was associated with lower odds of recurrence (OR = 0.64).
  • IGTA resulted in lower rates of permanent hoarseness (OR = 2.24) and transient hypoparathyroidism (OR = 5.67).
  • No significant differences were found in tumor progression or lymph node metastasis between the two treatments.

Why it matters

The findings highlight the potential of IGTA as a minimally invasive treatment for low-risk PTC, offering lower complication rates compared to traditional surgery. This information is crucial for clinicians considering treatment options for patients with T1N0M0 PTC.

Source

PubMed · PMID 42644737

Published in Balkan Med J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.